Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - Resubmission

生物医学卓越研究中心 (COBRE) 更新（第 2 阶段）CNTN - 重新提交

• 批准号: 10688038
• 负责人: JESSICA KIRKLAND CALDWELL
• 金额: $ 223.23万
• 依托单位: CLEVELAND CLINIC FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10688038
• 关键词: Affect; Applications Grants; Award; Biomedical Research; Brain imaging; Caliber; Centers of Research Excellence; Clinic; Clinical Research; Coin; Collaborations; Communities; Community Outreach; Data; Dedications; Development; Diagnostic Procedure; Enrollment; Environment; Equipment; Evaluation Reports; Faculty; Financial Support; Fostering; Funding; Future; Goals; Grant; Healthcare; Individual; Industry; Infrastructure; Institution; Knowledge; Leadership; Lifting; Manuscripts; Mentors; Methods; Monitor; National Institute of General Medical Sciences; Nerve Degeneration; Neurodegenerative Disorders; Neurosciences; Neurosciences Research; Nevada; Performance; Phase; Phenotype; Pilot Projects; Population; Population Heterogeneity; Preparation; Privatization; Process; Productivity; Proteomics; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Science; Scientist; Talents; Testing; Therapeutic Intervention; Training; United States National Institutes of Health; Universities; Writing; age related neurodegeneration; biomarker discovery; brain health; career; career development; cohort; data management; industry partner; infrastructure development; innovation; multidisciplinary; novel; programs; recruit; responsible research conduct; retiree; skills; southern nevada; statistics; synergism; translational neuroscience; volunteer

SUMMARY/ABSTRACT Overall Nevada (NV) is one of the 24 Institutional Development Award (IDeA) states affected by restricted research capacity. The overarching goal of our Center of Biomedical Research Excellence (COBRE) Center for Neurodegeneration and Translational Neuroscience (CNTN) is to establish translational neuroscience research infrastructure in Southern NV to develop innovative diagnostic methods and therapeutic interventions that can be applied across neurodegenerative disorders (NDD) and in diverse populations. The CNTN is highly significant for State representatives given the upcoming needs of age-related NDD healthcare due to the sustained increase in the population of NV, including retirees. Our thematically cohesive, multidisciplinary team comprises investigators from both the Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (LRCBH), and the University of Nevada Las Vegas (UNLV). During the first five years of COBRE support, the CNTN has transformed the environment for translational neuroscience research in Southern NV. The main accomplishments of CNTN Phase 1 are: 1- the creation of a Brain Imaging Department at LRCBH dedicated to research endeavors; 2- the building of a research cohort comprising NDD subjects who are deeply phenotyped; 3- the establishment of a Data Management and Statistics Core; 4- the inauguration of a Department of Brain Health, whose Founding Chair was a CNTN Junior Investigator (JI); 5- the forming of a Community Advisory Board to assist with community outreach activities aimed at inviting diverse individuals to volunteer in clinical research projects; and 6- the increase in the critical mass of investigators. A promising group of JIs have leveraged the resources compiled by the CNTN to carry out highly innovative research projects. All the JIs have graduated from the CNTN program with independent funding and promotion within local or external high caliber institutions. Our Assessment Unit has created new assessment methods based on a Science of Team Science approach to assess the performance of each individual CNTN Core and JI. They demonstrated that increasing the size of a scientific networking results in the inflation of scientific products. In Phase 2, the CNTN intends to develop the resources and processes necessary to reach sustainability. For this, we are revising the CNTN leadership to tackle growing responsibilities. The evaluation reports produced by our Assessment Unit will be utilized to elaborate our strategy, monitor progress, and make eventual adjustments. Specifically, we plan to foster infrastructure development, strengthen the career development of CNTN investigators, launch a pilot project program, and stimulate research productivity. We anticipate that our efforts will result in new collaborations with academic and industry partners, which will put the CNTN on the path for sustainability.

摘要/摘要 全面的 内华达州（NV）是受限制研究影响的24个机构发展奖（思想）国家之一 容量。我们生物医学研究中心卓越中心（COBRE）中心的总体目标 神经变性和转化神经科学（CNTN）是建立转化神经科学研究 南北NV的基础设施，以开发创新的诊断方法和治疗性干预措施 应用于神经退行性疾病（NDD）和不同人群中。 CNTN非常重要 鉴于由于持续增长而导致与年龄相关的NDD医疗保健需求的需求，州代表 在NV的人口中，包括退休人员。 我们的主题具有凝聚力的多学科团队由克利夫兰诊所Lou的调查员组成 鲁沃大脑健康中心，拉斯维加斯（LRCBH）和内华达大学拉斯维加斯大学（UNLV）。在 CNTN的前五年，CNTN改变了转化神经科学的环境 南北南部的研究。 CNTN阶段1的主要成就是：1-脑成像的创建 LRCBH的部门致力于研究努力； 2-由NDD组成的研究队列的建设 深深表现的受试者； 3-建立数据管理和统计核心； 4- 大脑健康部的就职典礼，其创始主席是CNTN初级调查员（JI）； 5- 成立社区咨询委员会，以协助旨在邀请多样化的社区外展活动 个人自愿参加临床研究项目； 6-调查人员的临界质量增加。一个 有前途的JIS团体利用了CNTN编制的资源来进行高度创新 研究项目。所有的JIS都从CNTN计划毕业，并具有独立的资金和晋升 在本地或外部高素质机构中。我们的评估部门创建了新的评估方法 基于团队科学方法的科学，以评估每个CNTN核心和JI的性能。 他们证明，增加科学网络的规模会导致科学产品的通胀。 在第2阶段，CNTN打算开发达到可持续性所需的资源和流程。为了 这，我们正在修改CNTN领导，以应对不断增长的责任。评估报告由 我们的评估单位将用于阐明我们的策略，监控进度并最终调整。 具体而言，我们计划促进基础设施发展，增强CNTN的职业发展 调查人员，启动试点项目计划，并刺激研究生产力。我们预计我们的努力 将与学术和行业合作伙伴进行新的合作，这将使CNTN成为 可持续性。

项目成果

Sex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume.

• DOI: 10.3233/jad-180028
• 发表时间: 2018
• 期刊: Journal of Alzheimer's disease : JAD
• 作者: Caldwell JZK;Berg JL;Shan G;Cummings JL;Banks SJ;Alzheimer’s Disease Neuroimaging Initiative
• 通讯作者: Alzheimer’s Disease Neuroimaging Initiative

Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume.

• DOI: 10.1186/s13195-017-0300-8
• 发表时间: 2017-09-12
• 期刊: Alzheimer's research & therapy
• 作者: Caldwell JZK;Berg JL;Cummings JL;Banks SJ;Alzheimer’s Disease Neuroimaging Initiative
• 通讯作者: Alzheimer’s Disease Neuroimaging Initiative

Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes.

• DOI: 10.1111/cts.12491
• 发表时间: 2018-03
• 期刊: Clinical and translational science
• 作者: Cummings J

Precision pharmacology for Alzheimer's disease.

• DOI: 10.1016/j.phrs.2018.02.014
• 发表时间: 2018-04
• 期刊: Pharmacological research
• 影响因子: 9.3
• 作者: Hampel H;Vergallo A;Aguilar LF;Benda N;Broich K;Cuello AC;Cummings J;Dubois B;Federoff HJ;Fiandaca M;Genthon R;Haberkamp M;Karran E;Mapstone M;Perry G;Schneider LS;Welikovitch LA;Woodcock J;Baldacci F;Lista S;Alzheimer Precision Medicine Initiative (APMI)
• 通讯作者: Alzheimer Precision Medicine Initiative (APMI)

Peripheral Biomarkers for Alzheimer's Disease: Update and Progress.

阿尔茨海默病的外周生物标志物：更新和进展。

• DOI: 10.1007/s40120-019-00171-6
• 发表时间: 2019
• 期刊: Neurology and therapy
• 影响因子: 3.7
• 作者: Sabbagh,MarwanN;Blennow,Kaj
• 通讯作者: Blennow,Kaj